About BioProtection Systems Corporation
BioProtection Systems Corporation is a publicly listed company based in Ames (United States) founded in 2005. Small molecule inhibitors for cancer are developed using IDO pathway. BioProtection Systems Corporation has raised $28.3 million across 5 funding rounds from investors including HHS. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and Diversified. Its legal entity is BioProtection Systems Corp. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Developer of small molecule inhibitors for the treatment of cancer. The company is developing novel immuno-oncology product candidates by using its checkpoint inhibitor platform. It uses the indoleamine 2,3-dioxygenase (IDO) pathway that regulates body immune response by suppressing T-cell function. It has also developed two IDO pathway inhibitors such as GDC-0919 and indoximod that is being developed in combination with antibodies and chemotherapy for the treatment of breast cancer, pancreatic cancer, glioblastoma, melanoma, and others.
- Total Equity Funding$28.3M (USD)
in 5 rounds
- Latest Funding Round$972.87K (USD), Series B
Oct 2010
- Investors
Funding Insights of BioProtection Systems Corporation
BioProtection Systems Corporation has successfully raised a total of $28.3M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $972.87 thousand completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $28.3M
- Total Rounds 5
- Last Round Series B — $972,873
- First Round $17.3M
(Oct 2008)
- Investors Count 1
All 5 funding rounds of BioProtection Systems Corporation with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2010 | $972,873 | Series B | – | – | – |
| Jul 2010 | $2.53M | Series B | – | – | – |
| Apr 2010 | $599,895 | Grant | – | – | |
| Jul 2009 | $7.5M | Series B | – | – | – |
| Oct 2008 | $17.3M | Series B | – | – | – |
1 investors in total: 1 institutional.
Investors in BioProtection Systems Corporation
BioProtection Systems Corporation has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for BioProtection Systems Corporation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioProtection Systems Corporation
3 dated milestones of BioProtection Systems Corporation across 5 years, from founding to its latest funding, stage changes and deals.
- Founded BioProtection Systems Corporation is founded.
- Funding First funding round of $17.3M.
- Funding Latest funding round, Series B, of $973K.
Competitors of BioProtection Systems Corporation
BioProtection Systems Corporation has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of BioProtection Systems Corporation
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioProtection Systems Corporation
The website of BioProtection Systems Corporation (linkp.com) receives about 1.8K visits a month and ranks #9,022,027 among all websites worldwide, #7,566 in Biotechnology and Pharmaceuticals.
- Monthly visits1.8K
- Global rank#9,022,027
among all websites
- Category rank#7,566
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit1.5
- Average visit14 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with BioProtection Systems Corporation. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
neuralstem.com | neuralstem.com | 100% | – | ||
newlinkgenetics.com | newlinkgenetics.com | 95% | – | ||
| anaptysbio.com | 92% | 10.8K | #1,418,623 | View details | |
| nektar.com | 91% | 19.6K | #959,308 | View details | |
| seagen.com | 90% | 1.1K | #7,340,146 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for BioProtection Systems Corporation
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as BioProtection Systems Corporation (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioprotection Systems Corporation
Complete news archive for BioProtection Systems Corporation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioProtection Systems Corporation
BioProtection Systems Corporation was founded in 2005 and raised its 1st funding round 3 years after it was founded.
BioProtection Systems Corporation is headquartered in Ames, United States. It is registered at Ames, Iowa, United States.
BioProtection Systems Corporation is a funded company, having raised a total of $28.3M across 5 funding rounds to date. The company's 1st funding round was a Series B of $17.3M, raised on Oct 2008.
Developer of small molecule inhibitors for the treatment of cancer. The company is developing novel immuno-oncology product candidates by using its checkpoint inhibitor platform. It uses the indoleamine 2,3-dioxygenase (IDO) pathway that regulates body immune response by suppressing T-cell function. It has also developed two IDO pathway inhibitors such as GDC-0919 and indoximod that is being developed in combination with antibodies and chemotherapy for the treatment of breast cancer, pancreatic cancer, glioblastoma, melanoma, and others.
BioProtection Systems Corporation has 1 investor. Key investors include HHS.
BioProtection Systems Corporation operates through Bioprotection Systems Corp.